Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 09/27 07:00:07 pm
119.01 USD   +1.04%
04:19p JOHNSON & JOHNS : Two US companies eye Seagate land in Batu Kawan
09/26 JOHNSON & JOHNS : FDA Approves STELARA® (Ustekinumab) for Treatment ..
09/26 JOHNSON & JOHNS : Research finds talc doesn't cause cancer; juries d..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2012 | 11:51pm CEST
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
04:19p JOHNSON & JOHNSON : Two US companies eye Seagate land in Batu Kawan
09/26 JOHNSON & JOHNSON : FDA Approves STELARA® (Ustekinumab) for Treatment of Adults ..
09/26 JOHNSON & JOHNSON : Research finds talc doesn't cause cancer; juries disagree
09/25 JOHNSON & JOHNSON : The Philadelphia Inquirer Kellie Patrick Gates column
09/25 JOHNSON & JOHNSON : Dennis W. Weaver
09/24 PFIZER INC. : vs. Johnson & Johnson
09/23 JOHNSON & JOHNSON : Michael Ullmann Appointed to Princeton Area Community Founda..
09/23 JOHNSON & JOHNSON : Parametric Portfolio Associates buys $772,134,349 stake in J..
09/22 JOHNSON & JOHNSON : U.S. FDA Approves INVOKAMET® XR (Canagliflozin / Metformin H..
09/21 GLOBAL BABY BATH PRODUCT MARKET 2016 : Mamas and Papas, Johnson and Johnson, Fis..
More news
Sector news : Pharmaceuticals - NEC
08:49aDJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12:09p My 85 Stock Portfolio Evaluation Of Want To Buy Prices And Yields For Purchas..
09/26 FDA OKs Johnson & Johnson's Stelara for Crohn's disease
09/26 MY 4% DIVIDEND YIELD PORTFOLIO : Q3'16 Summary And Plans For Q4
09/26 GILEAD : Ways To Unlock Shareholder Value
09/26 QUINTILES TRANSNATIONAL : A Total Return Growth Biopharmaceutical (Part 7 Single..
Advertisement
Financials ($)
Sales 2016 72 075 M
EBIT 2016 21 925 M
Net income 2016 16 508 M
Finance 2016 14 428 M
Yield 2016 2,66%
P/E ratio 2016 20,06
P/E ratio 2017 17,67
EV / Sales 2016 4,27x
EV / Sales 2017 4,00x
Capitalization 322 232 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 127 $
Spread / Average Target 7,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
GLAXOSMITHKLINE PLC20.39%103 357
More Results